Please use this identifier to cite or link to this item:
http://hdl.handle.net/11455/68150
標題: | Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from Lonicera hypoglauca Miq | 作者: | Wang, S.Y. Tseng, C.P. Tsai, K.C. Lin, C.F. Wen, C.Y. Tsaye, H.S. Sakamoto, N. Tseng, C.H. Cheng, J.C. |
關鍵字: | Hepatitis C virus;Lonicera hypoglauca Miq.;Pheophytin a;Replicon;cells;serine-protease;rna replication;cell-culture;inhibition;infection;ribavirin;variants;japonica;chinese;system | Project: | Biochemical and Biophysical Research Communications | 期刊/報告no:: | Biochemical and Biophysical Research Communications, Volume 385, Issue 2, Page(s) 230-235. | 摘要: | Chronic hepatitis C virus (HCV) infection is a worldwide public issue. In this study, we performed bioactivity-guided screening of the Lonicera hypoglauca Miq. crude extracts to find for naturally chemical entities with anti-HCV activity. Pheophytin a was identified from the ethano-soluble fraction of L. hypoglauca that elicited dose-dependent inhibition of HCV vital proteins and RNA expression in both replicon cells and cell culture infectious system. Computational modeling revealed that pheophytin a can bind to the active site of HCV-NS3, suggesting that NS3 is a potent molecular target of pheophytin a. Biochemical analysis further revealed that pheophytin a inhibited NS3 serine protease activity with IC(50) = 0.89 mu M. Notably, pheophytin a and IFN alpha-2a elicited synergistic anti-HCV activity in replicon cells with no significant cytotoxicity. This study thereby demonstrates for the first time that pheophytin a is a potent HCV-NS3 protease inhibitor and offers insight for development of novel anti-HCV regimens. (C) 2009 Elsevier Inc. All rights reserved. |
URI: | http://hdl.handle.net/11455/68150 | ISSN: | 0006-291X | DOI: | 10.1016/j.bbrc.2009.05.043 |
Appears in Collections: | 期刊論文 |
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.